نتائج البحث - Daniel Mulkerin

  • يعرض 1 - 11 نتائج من 11
تنقيح النتائج
  1. 1
    A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors

    A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors حسب Ning Jin, Sam Joseph Lubner, Daniel Mulkerin, Saurabh Rajguru, Lakeesha Carmichael, Herb Chen, Kyle D. Holen, Noelle K. LoConte

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Precision medicine in colorectal cancer: the molecular profile alters treatment strategies

    Precision medicine in colorectal cancer: the molecular profile alters treatment strategies حسب Nguyen H. Tran, Ludimila Cavalcante, Sam Joseph Lubner, Daniel Mulkerin, Noelle K. LoConte, Linda Clipson, Kristina A. Matkowskyj, Dustin A. Deming

    منشور في 2015
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma

    A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma حسب Tabraiz A Mohammed, Kyle D. Holen, Renata Jaskula‐Sztul, Daniel Mulkerin, Sam Joseph Lubner, William R. Schelman, Jens C. Eickhoff, Herbert Chen, Noelle K. LoConte

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

    Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-643... حسب Patricia LoRusso, Karthik Venkatakrishnan, Ramesh K. Ramanathan, John Sarantopoulos, Daniel Mulkerin, Stephen Shibata, Anne Hamilton, Afshin Dowlati, Sridhar Mani, Michelle A. Rudek, Chris H. Takimoto, Rachel Neuwirth, Dixie-Lee Esseltine, S. Percy Ivy

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

    A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer حسب Dustin A. Deming, Ludimila Cavalcante, Sam Joseph Lubner, Daniel Mulkerin, Noelle K. LoConte, Jens C. Eickhoff, Jill Kolesar, Suzanne Fioravanti, Tim F. Greten, Kathryn Compton, Austin Doyle, George Wilding, Austin G. Duffy, Glenn Liu

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

    Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Org... حسب Ramesh K. Ramanathan, Merrill J. Egorin, Chris H. Takimoto, Scot C. Remick, James H. Doroshow, Patricia LoRusso, Daniel Mulkerin, Jean L. Grem, Anne Hamilton, Anthony J. Murgo, Douglas M. Potter, Chandra P. Belani, Michael Hayes, Bin Peng, S. Percy Ivy

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function

    Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function حسب Chris H. Takimoto, Martin A. Graham, G. Lockwood, Chee M. Ng, Andrew Goetz, Dennis Greenslade, Scot C. Remick, Sunil Sharma, Sridhar Mani, Ramesh K. Ramanathan, Timothy W. Synold, James H. Doroshow, Anne Hamilton, Daniel Mulkerin, Percy Ivy, Merrill J. Egorin, Jean L. Grem

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

    Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study حسب Stephen Shibata, Vincent Chung, Timothy W. Synold, Jeff Longmate, A. Benjamin Suttle, Lone H. Ottesen, Heinz-Josef Lenz, Shivaani Kummar, R. Donald Harvey, Anne Hamilton, Bert H. O’Neil, John Sarantopoulos, Patricia LoRusso, Michelle A. Rudek, Afshin Dowlati, Daniel Mulkerin, Chandra P. Belani, Leena Gandhi, S. Cecilia Lau, S. Percy Ivy, Edward M. Newman

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

    Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized... حسب Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A. Meyerhardt, Deborah Schrag, Claire Greene, Bert H. O’Neil, James N. Atkins, Scott Berry, Blasé N. Polite, Eileen M. O’Reilly, Richard M. Goldberg, Howard S. Höchster, Richard L. Schilsky, Monica M. Bertagnolli, Anthony B. El-Khoueiry, Peter Watson, Al B. Benson, Daniel Mulkerin, Robert J. Mayer, Charles D. Blanke

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer

    Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer حسب Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A. Meyerhardt, Deborah Schrag, Claire Greene, Bert H. O’Neil, James N. Atkins, Scott Berry, Blasé N. Polite, Eileen M. O’Reilly, Richard M. Goldberg, Howard S. Höchster, Richard L. Schilsky, Monica M. Bertagnolli, Anthony B. El-Khoueiry, Peter J. Watson, Al B. Benson, Daniel Mulkerin, Robert J. Mayer, Charles D. Blanke

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity

    Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity حسب Jeremy D. Kratz, Shujah Rehman, Katherine A. Johnson, Amani A. Gillette, Aishwarya Sunil, Peter F. Favreau, Cheri A. Pasch, Devon Miller, Lucas C. Zarling, Austin H. Yeung, Linda Clipson, Samantha J. Anderson, Alyssa K Steimle, Carley M. Sprackling, Kayla K. Lemmon, Daniel E. Abbott, Mark E. Burkard, M. Bassetti, Jens C. Eickhoff, Eugene F. Foley, Charles P. Heise, Randall J. Kimple, Elise H. Lawson, Noelle K. LoConte, Sam Joseph Lubner, Daniel Mulkerin, Kristina A. Matkowskyj, Cristina B. Sanger, Nataliya V. Uboha, Sean J. McIlwain, Irene M. Ong, Evie H. Carchman, Melissa C. Skala, Dustin A. Deming

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: